secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093298
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences reports Q2 2024 net loss of $20.3M; cash $187.4M into H2 2026
------------------------------------------------------------------------------

- Net loss of $20.3M in Q2 2024 vs $18.3M in Q2 2023; R&D spend $16.9M, G&A $5.9M.
- Cash and marketable securities $187.4M as of June 30, 2024; expected to fund operations into H2 2026.
- Phase 3 CoMpass trial for small choroidal melanoma continues enrollment globally; target ~100 patients.
- Early NMIBC Phase 1 data expected at virtual urologic oncology event in October 2024.
- Phase 2 end-of-study data in small choroidal melanoma at Retina Society Annual Meeting Sept 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024093298/0000950170-24-093298-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017024093298/aura-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093298

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer